Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

45.6K
Overview
45.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

711
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

753
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
753
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

74.9K
Overview
74.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammatory Preconditioning Reprograms Mesenchymal Stromal Cell-Derived Extracellular Vesicles into Distinct Functional States for Immunomodulation and Wound Healing.

Stem cells and development·2026
Same author

Spatially controlled Islet delivery into a bioengineered vascular Niche improves subcutaneous transplantation.

Biomedical microdevices·2026
Same author

Biodegradable nanofibrous drug-eluting seed for sustained intratumoral immunotherapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Overcoming intratumoral transport barriers: Advances in local immunotherapy delivery platforms.

Advanced drug delivery reviews·2026
Same author

Pancreatic Islet Isolation and Purification from Lewis Rats Using Enzymatic Digestion and Density-Gradient Separation.

Journal of visualized experiments : JoVE·2026
Same author

Profiling Localized Immunomodulation and Drug Biodistribution within a Subcutaneous Vascularized Niche for Cell Transplantation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Related Experiment Video

Updated: Oct 5, 2025

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.4K

Engineered implantable vaccine platform for continuous antigen-specific immunomodulation.

Dixita Ishani Viswanath1, Hsuan-Chen Liu2, Simone Capuani3

  • 1Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA; Texas A&M University College of Medicine, Bryan & Houston, TX, USA.

Biomaterials
|January 23, 2022
PubMed
Summary

A novel implantable device, NanoLymph, delivers sustained immune stimulants and antigens to activate immune cells and generate antigen-specific T lymphocytes for cancer vaccines, overcoming limitations of current dendritic cell strategies.

Keywords:
Cancer vaccineImmunomodulationIn situ deliveryLocal controlled releaseOncoimmunotherapySubcutaneous implant

More Related Videos

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.3K
Author Spotlight: Developing Immunocompetent Organ-on-Chip Models for Infectious Disease Research
08:48

Author Spotlight: Developing Immunocompetent Organ-on-Chip Models for Infectious Disease Research

Published on: May 24, 2024

2.0K

Related Experiment Videos

Last Updated: Oct 5, 2025

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination
11:07

Whole-animal Imaging and Flow Cytometric Techniques for Analysis of Antigen-specific CD8+ T Cell Responses after Nanoparticle Vaccination

Published on: April 29, 2015

13.4K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.3K
Author Spotlight: Developing Immunocompetent Organ-on-Chip Models for Infectious Disease Research
08:48

Author Spotlight: Developing Immunocompetent Organ-on-Chip Models for Infectious Disease Research

Published on: May 24, 2024

2.0K

Area of Science:

  • Biomedical Engineering
  • Immunology
  • Oncology

Background:

  • Current ex vivo dendritic cell (DC) cancer vaccine strategies face challenges in manufacturing, delivery, and clinical efficacy.
  • There is a need for innovative approaches to achieve sustained, localized antitumor immunity.

Purpose of the Study:

  • To design and validate the NanoLymph, an implantable device for in situ antigen-specific antitumor immunomodulation.
  • To assess the biocompatibility, mechanical stability, and drug release capabilities of the NanoLymph.
  • To evaluate the NanoLymph's efficacy in recruiting and activating immune cells and generating antigen-specific T lymphocytes.

Main Methods:

  • Development of a dual-reservoir implantable device (NanoLymph) for sustained release of immune stimulants and antigens.
  • Characterization of NanoLymph biocompatibility and mechanical properties.
  • In vivo assessment of transcutaneous refilling for prolonged drug release.
  • Evaluation of local immune cell recruitment and activation (DCs) and generation of antigen-specific T lymphocytes in a murine model.

Main Results:

  • NanoLymph demonstrated biocompatibility and mechanical stability.
  • Minimally invasive transcutaneous refilling enabled prolonged drug release.
  • Local elution of GMCSF and Resiquimod successfully recruited and activated DCs within 14 days.
  • Antigen-specific T lymphocytes were generated in situ, indicating effective immunomodulation.

Conclusions:

  • The NanoLymph device facilitates in situ immunomodulation for therapeutic cancer vaccines.
  • This approach offers a viable alternative to ex vivo DC-based strategies.
  • NanoLymph shows potential for long-term tumor elimination and durable immunomodulation.